Biogen is also eyeing the Asian market and will continue EMA and CHMP talks regarding Aduhelm next steps in Europe, but even with a European approval, reimbursement would be an uphill battle, noted RBC Capital Markets analyst Brian Abrahams. (Biogen)
European regulators don
